Targets › SCNN1B
4 programs from 4 companies in 11 trials: 7 Phase 2, 2 Phase 4, 1 Phase 1, 1 Phase 3; Cardiovascular, Neurology, Gastroenterology; next expected readout Dec 2026.
This is one of the three pore-forming subunits of the heterotrimeric epithelial sodium channel (ENaC), a critical regulator of sodium balance and fluid homeostasis. ENaC operates in epithelial tissues, where it mediates the electrodiffusion of sodium ions from extracellular fluid through the apical membrane of cells, with water following osmotically. (UniProt, P51168)
Open in Phaseline: the race on SCNN1B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Odense University Hospital | Capsule FMT Amiloride-sensitive sodium channel, ENaC blocker | GLP1R, ATP4A, ATP4B, CTLA4, FKBP1A, TNF, PDCD1, SCNN1A, SCNN1B, SCNN1G | Phase 4 | Gastroesophageal Reflux; Colitis; Chronic Kidney Disease(CKD); Postmenopausal Women … | Dec 2026 |
| Assistance Publique - Hôpitaux de Paris | Amiloride Amiloride-sensitive sodium channel, ENaC blocker | SCNN1A, SCNN1B, SCNN1G | Phase 4 | Bipolar Disorder | – |
| Centre Hospitalier Universitaire de Nice | Amiloride Amiloride-sensitive sodium channel, ENaC blocker | SCNN1A, SCNN1B, SCNN1G | Phase 2 | Migraine With Aura | Dec 2027 |
| Yale University | Amiloride Amiloride-sensitive sodium channel, ENaC blocker | SCNN1A, SCNN1B, SCNN1G | Phase 1 | Heart Failure | Jun 2028 |
Heart Failure (1) Migraine With Aura (1) Gastroesophageal Reflux (1) Colitis (1) Chronic Kidney Disease(CKD) (1) Postmenopausal Women (1) Type 2 Diabetes (1) Rheumatoid Arthritis (1) Healthy (1) Cancer of Rectum (1) Bipolar Disorder (1)
small molecule (3), protein or peptide (1)
Yale University (1) Centre Hospitalier Universitaire de Nice (1) Odense University Hospital (1) Assistance Publique - Hôpitaux de Paris (1)
SCNN1A (4) SCNN1G (4) GLP1R (1) ATP4A (1) ATP4B (1) CTLA4 (1) FKBP1A (1) TNF (1) PDCD1 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.